Onabotulinumtoxin A
PreclinicalSmall molecule
LundbeckOnabotulinumtoxin A is one of 6 small molecule programs targeting Chronic Pelvic Pain. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Chronic Pelvic Pain
#DrugCompanyPhaseTrials
1Activella
Eli LillyPhase 3
Psilocybin
COMPASS PathwaysPhase 1
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Pharmacotherapy
UUniversity of Pittsburgh
Preclinical
Botulinum Neurotoxin
TThe University of Texas Health Science Center, Houston
Phase 1
Onabotulinumtoxin A
LundbeckPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pain1 trial
Reduction of Bladder Injection Pain With Belladonna Opiate Suppository
Completed·—·Phase 4·NCT02600715·26 enrolled
3 more indications
Stress urinary incontinence1 trial
Chronic Pelvic Pain1 trial
Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
Completed·—·N/A·NCT02369068·21 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Onabotulinumtoxin A. EMBL-EBI & Wellcome Sanger Institute.
- [4]